How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition…
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults…
By Christopher Rudolf, Volv Global An AI Methodology for Finding Patients with Rare Diseases: Volv Global’s inTrigue Finding patients with…
By Volv Global SA and WODC EU contributors Executive Summary For decades, the pharmaceutical industry has faced the same…